Literature DB >> 1722483

Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.

A Nakao1, A Virji, Y Iwaki, B Carr, S Iwatsuki, E Starzl.   

Abstract

Des-gamma-carboxy prothrombin (DCP), a protein induced by vitamin K absence or antagonist-II (PIVKA-II) was measured by an enzyme immunoassay (E-1023) using anti-DCP monoclonal antibody in 92 patients with various hepatobiliary diseases. Thirty-six of the 38 patients (94.7%) with hepatocellular carcinoma (HCC) had abnormal DCP levels greater than 0.1 arbitrary unit (AU)/ml, but only 18 of the 35 patients (51.4%) had AFP greater than 100 ng/ml (suspicious levels for HCC). There was no correlation between plasma or serum DCP and serum alpha-fetoprotein (AFP) levels. Serum alpha fetoprotein was elevated (above 20 ng/ml) in 23 of the 35 patients (65.7%), and DCP was elevated in all of the remaining 12 patients with normal AFP. DCP levels returned to normal levels following curative hepatic resection or orthotopic liver transplantation for HCC. DCP is a useful tumor marker in the diagnosis and postoperative monitoring of patients with HCC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722483      PMCID: PMC2952478     

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  9 in total

1.  Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin.

Authors:  H A Liebman
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

Review 2.  Vitamin K-dependent formation of gamma-carboxyglutamic acid.

Authors:  J Stenflo; J W Suttie
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

3.  Detection of vitamin K deficiency by use of an enzyme-linked immunosorbent assay for circulating abnormal prothrombin.

Authors:  K Motohara; Y Kuroki; H Kan; F Endo; I Matsuda
Journal:  Pediatr Res       Date:  1985-04       Impact factor: 3.756

4.  Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study.

Authors:  H Okuda; H Obata; T Nakanishi; R Furukawa; E Hashimoto
Journal:  J Hepatol       Date:  1987-06       Impact factor: 25.083

5.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

6.  Clinical observations during a relatively early stage of hepatocellular carcinoma, with special reference to serum alpha-fetoprotein levels.

Authors:  K Okuda; K Kotoda; H Obata; N Hayashi; T Hisamitsu
Journal:  Gastroenterology       Date:  1975-07       Impact factor: 22.682

7.  Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma.

Authors:  S Fujiyama; T Morishita; O Hashiguchi; T Sato
Journal:  Cancer       Date:  1988-04-15       Impact factor: 6.860

8.  Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.

Authors:  K Motohara; F Endo; I Matsuda; T Iwamasa
Journal:  J Pediatr Gastroenterol Nutr       Date:  1987 Jan-Feb       Impact factor: 2.839

9.  Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.

Authors:  H A Liebman; B C Furie; M J Tong; R A Blanchard; K J Lo; S D Lee; M S Coleman; B Furie
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

  9 in total
  7 in total

Review 1.  Vitamin K effects in human health: new insights beyond bone and cardiovascular health.

Authors:  Maria Fusaro; Maurizio Gallieni; Camillo Porta; Thomas L Nickolas; Pascale Khairallah
Journal:  J Nephrol       Date:  2019-12-19       Impact factor: 3.902

2.  A young woman with liver cancer.

Authors:  Celina S Ang; Richard K Do; Ali Shamseddine; Eileen M O'Reilly; Ali Haydar; Ashwaq Al-Olayan; Walid Faraj; Fouad Boulos; Mohamed Naghy; Dorothy Makanjoula; Hassan Farran; Hassan Sibai; David Wehbe; David P Kelsen; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

3.  Growth inhibitory actions of prothrombin on normal hepatocytes: influence of matrix.

Authors:  Brian I Carr; Siddhartha Kar; Meifang Wang; Ziqiu Wang
Journal:  Cell Biol Int       Date:  2007-03-19       Impact factor: 3.612

4.  Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.

Authors:  Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

5.  Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.

Authors:  Rentao Yu; Xiaomei Xiang; Zhaoxia Tan; Yi Zhou; Haoliang Wang; Guohong Deng
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

Review 6.  Vitamins as Possible Cancer Biomarkers: Significance and Limitations.

Authors:  Sascha Venturelli; Christian Leischner; Thomas Helling; Markus Burkard; Luigi Marongiu
Journal:  Nutrients       Date:  2021-11-01       Impact factor: 5.717

7.  Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population.

Authors:  Rentao Yu; Shitao Ding; Wenting Tan; Shun Tan; Zhaoxia Tan; Shiqing Xiang; Yi Zhou; Qing Mao; Guohong Deng
Journal:  Hepat Mon       Date:  2015-07-22       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.